Bone Marrow Transplantation (BMT) and Immunotherapy Fellowship

Specialized Training for Physicians Interested in BMT and Immunotherapies

This intensive one-year fellowship is designed to prepare physicians for academic careers focused on transplantation and cellular therapy. Our program started in the late 1960s with Nobel prize winner, E. Donnall Thomas, and his team of transplant physicians and clinical staff, who discovered a way to treat advanced leukemia by eradicating malignant white blood cells in the bone marrow using high doses of chemotherapy and radiation, and then replacing them with healthy donor cells. We now have 60 clinical faculty members at Fred Hutch and the University of Washington who specialize in transplantation and cellular therapy and serve as mentors to trainees from around the world.

 

Program Overview

The BMT and Immunotherapy fellowship is an intense, year-long program to prepare hematology-oncology physicians to become adept in blood and marrow transplantation (BMT) and immunotherapy (IMTX) services.

You will have the opportunity to work with world renowned faculty who are on the cutting edge of novel treatments for malignant and non-malignant diseases. The fellow will rotate through outpatient and inpatient BMT (autologous and allogeneic, long-term follow-up) and IMTX services, and initially function as a primary care provider with increasing levels of patient care responsibility over the course of the year. Approximately 8 months will be devoted to clinical activities with the remaining time available to participate in research projects.

The program accepts applications in the spring and summer for programs starting July 1 the following calendar year.  
  

Fellowship Co-Directors

Marco Mielcarek, M.D.

Marco Mielcarek, M.D.

Professor
Clinical Research Division, Fred Hutch

Medical Director
Adult Blood and Marrow Transplantation,
Fred Hutch / Seattle Cancer Care Alliance

David Maloney, M.D., Ph.D.

Professor
Clinical Research Division, Fred Hutch

Medical Director
Cellular Immunotherapy, Immunotherapy Integrated Research Center (IIRC), Fred Hutch

Leonard and Norma Klorfine Endowed Chair for Clinical Research, Fred Hutch

Committee Members

Stephanie Lee, M.D., M.P.H.

Stephanie Lee, M.D., M.P.H.

Professor and Associate Director
Clinical Research Division, Fred Hutch

David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research, Fred Hutch

Mike Linenberger, M.D.

Mike Linenberger, M.D.

Professor
Clinical Research Division, Fred Hutch

Program Director
Hematology/Oncology Fellowship, University of Washington

Medical Director
Apheresis and Cellular Therapy, Seattle Cancer Care Alliance

Robert and Phyllis Henigson Endowed Chair, University of Washington

Masumi Ueda, M.D., M.A.

Masumi Ueda, M.D., M.A.

Assistant Professor                              Clinical Research Division, Fred Hutch

Assistant Professor                             Division of Medical Oncology  University of Washington School of Medicine

Assistant Medical Director             Inpatient Blood and Marrow Transplantation
Seattle Cancer Care Alliance

 Geoff Hill, M.D., F.R.A.C.P., F.R.C.P.A.

Geoff Hill, M.D., F.R.A.C.P., F.R.C.P.A.

Professor
Clinical Research Division, Fred Hutch

Scientific Director
Immunotherapy Integrated Research Center (IIRC), Fred Hutch

Director of Hematopoietic Stem Cell Transplantation
Fred Hutch / Seattle Cancer Care Alliance

José Carreras / E. Donnall Thomas Endowed Chair for Cancer Research, Fred Hutch

Application Instructions

The application system is currently accepting materials for the July 2022-June 2023 academic year. 

Applicants Should Submit the Following Materials

+
  • C.V.
  • Statement of clinical and research interests
  • Personal statement outlining your interests in the fellowship program
  • A diversity, inclusion and mentoring statement
  • Contact information for at least three professional references (including your hem/onc fellowship director)

Qualifications

+
  • The ideal candidate should have an interest in hematopoietic cell transplantation and/or immunotherapy and should have completed a fellowship in hematology or hematology-oncology. 
  • All applicants must have a medical doctorate (or foreign equivalent) and be board eligible/certified.
  • US graduates must be ABIM board eligible/certified in Hematology and/or Oncology.
  • In order to be eligible for sponsorship for an H-1B visa, graduates of foreign medical schools must show successful completion of all three steps of the U.S. Medical Licensing Exam (USMLE) and be ECFMG certified.

Diversity

+

We believe that the diversity of our fellows, residents, medical students, staff and faculty is a fundamental element of our ability to ensure that all our patients and families receive the highest-quality care – no matter their race, ethnicity, language, literacy, age, gender, gender identity, sexual orientation, religion, disability or finances. Our objective is to create a community that encourages participation and connection, and that values and includes each individual's unique contribution, in every aspect of our mission and practice.

Questions about the program can be sent to:

Andrea Tate
Administrative Manager, Faculty Affairs

Last Modified, October 14, 2021